araag2/HINT huggingface dataset:
Clinical trial NCT02586961 (phase 2/phase 3, status: terminated)
Conditions: children, bronchiolitis
ICD codes: Y93.6A, Y92.110, Y92.111, Y92.112, Y92.113, Y92.114, Y92.115, J21.9, J84.115, J21.1, J21.0, J21.8
Drugs: 0.9% saline solution, oral betamethasone placebo, adrenaline, oral betamethasone
SMILES: [Na+].[Cl-], [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CNC[C@H](O)C1=CC(O)=C(O)C=C1, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    removal of adrénaline lots for safety reasons.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Infants aged 6 weeks to 12 months admitted in paediatric emergency

          -  First episode of acute bronchiolitis defined as: expiratory dyspnea with breath
             slowing and/or sibilants and/or crackles preceded by (or associated with) a
             nasopharyngitis more or less febrile

          -  Respiratory distress assessment index score (RDAI) of 4 to 15 after a nasopharyngeal
             clearance

          -  Agreement of at least one of the parents for his child to participate in biomedical
             research

          -  Affiliation to social security (beneficiary or entitled), except beneficiary of State
             medical help

        Exclusion Criteria:

          -  Prematurity (less than 37 weeks of gestation)

          -  Antecedent of invasive respiratory ventilation during neonatal period

          -  Antecedent of lung or chronic cardiac pathology of wich rhythm disorder, acute
             obstructive cardiomyopathy and coronary insufficiency

          -  Immune deficiency

          -  Active viral infection (hepatitis, zona, herpes, varicella, HIV)

          -  Proven or suspected tuberculosis

          -  Exposure to varicella during 15 days before inclusion

          -  Severe distress (defined as one of following signs: a pulse rate >200/min, respiratory
             rate >80/min, RDAI score >15, neurological disorders)

          -  Nebulization (aerosol spray) of Salbutamol or other bronchodilator treatment during
             the 24 hours before the inclusion

          -  Inhalation (spray) of Salbutamol during the preceding 24 hours

          -  Oral or inhaled corticosteroids during the preceding 2 weeks

          -  Previous episode of wheezing or ascertained diagnosis of asthma

          -  Hypersensitivity to one of the constituting of oral betamethasone

          -  Vaccination by living vaccine during the preceding 2 weeks
Clinical trial NCT02588781 (phase 2, status: recruiting)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          1. Subject is at least 20 years of age.

          2. Written and voluntary informed consent understood, signed and dated.

          3. They must have refractory or progressive colorectal cancer for which there is no
             further curative therapy available.

          4. Subject able to adhere to the study visit schedule and other protocol requirements.

          5. ECOG 0-2

          6. At least one measurable lesion that can be accurately assessed by imaging or physical
             examination at baseline and following up visits.

          7. Must have a life expectancy of 3 months or more

          8. Demonstrate adequate organ function

          9. Negative urine or serum pregnancy test within 28 days of study treatment

         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy
             of the tissue sample quality for assessment of biomarker status.

        Exclusion Criteria:

          1. ECOG ≥ 3

          2. History of malignancy in the last 5 years.

          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis
             C.

          4. Breast-feeding or pregnant female

          5. Patients can not the administration of Folic acid or Vitamin B12.

          6. Before treatment with Pemetrexed.

          7. Patients who can not swallow oral medication.

          8. The most recent treatment with the clinical trial for the drug for 14 days prior to
             enrollment.

          9. Systemic chemotherapy within three weeks after the administration of the last before
             the test treatment, radiation therapy patients who had been administered.

         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in
             progress (> CTCAE1 grade).

         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or
             4 grade.

         12. Subject who experienced a recent myocardial infarction, including severe/unstable
             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,
             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram
             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and
             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past
             year.
Clinical trial NCT02589236 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: cavosonstat, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have been treated with lumacaftor/ivacaftor for at least 8 weeks prior
             to Day 1 (start of dosing)

          -  A history of Sweat Chloride (SC) ≥ 60 mEq/L by quantitative pilocarpine iontophoresis
             test (QPIT) (either before or after starting lumacaftor/ivacaftor treatment)

          -  Body weight ≥ 40 kg

          -  ppFEV1 40 - 85 % predicted (inclusive) at screening

          -  Oxygen saturation ≥ 90% breathing ambient air at screening

        Exclusion Criteria:

          -  Any acute infection that requires treatment or hospitalization within 2 weeks of Study
             Day 1

          -  Colonization with organisms associated with more rapid decline in pulmonary status,
             such as Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus

          -  Any change in the regimen for chronic therapies for CF lung disease (e.g., Pulmozyme®,
             hypertonic saline, Azithromycin, TOBI®, Cayston®) within 4 weeks of Study Day 1

          -  Are pregnant, planning a pregnancy, or breast-feeding at screening

          -  Blood hemoglobin < 10 g/dL at screening

          -  Serum albumin < 2.5 g/dL at screening

          -  Abnormal liver function defined as ≥ 3 x upper limit of normal (ULN)

          -  History of abnormal renal function within 3 months of screening

          -  History of ventricular tachycardia or other clinically significant ventricular
             arrhythmias

          -  History, including the screening assessment, of prolonged QT and/or QTcF (Fridericia's
             correction) interval

          -  History of solid organ or hematological transplantation

          -  History of alcohol abuse or drug abuse

          -  Ongoing participation in another therapeutic clinical trial

          -  Use of continuous (24 hr/day) or nocturnal supplemental oxygen
Clinical trial NCT02589665 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: mirikizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have moderate to severe active UC as defined by a Mayo score of 6 to 12 with an
             endoscopic subscore ≥2 within 14 days before the first dose of study treatment (note:
             a partial Mayo score of at least 4 and other eligibility criteria must have been met
             before endoscopy is performed as a study procedure)

          -  Have evidence of UC extending proximal to the rectum (≥15 centimeters [cm] of involved
             colon)

          -  Up-to-date colorectal cancer surveillance (performed according to local standard), for
             subjects with family history of colorectal cancer, personal history of increased
             colorectal cancer risk, age >50 years, or other known risk factor

          -  Participants must either: be naive to biologic therapy (eg, tumor necrosis factor
             [TNF] antagonists or vedolizumab) and have at least 1 of the following: inadequate
             response or failure to tolerate current treatment with oral or intravenous
             corticosteroids or immunomodulators (6-mercaptopurine or azathioprine) or history of
             corticosteroid dependence (an inability to successfully taper corticosteroids without
             return of UC) OR have received treatment with 1 or more biologic agents (eg, TNF
             antagonists or vedolizumab) at doses approved for the treatment of UC with documented
             history of failure to respond to or tolerate such treatment

        Exclusion Criteria:

          -  Have been diagnosed with indeterminate colitis, proctitis (distal disease involving
             the rectum only; less than 15 cm from the anal verge) or Crohn's Disease

          -  Have had surgery for treatment of UC or are likely to require surgery for UC during
             the study

          -  Have received any of the following for treatment of UC: cyclosporine or thalidomide
             within 30 days of screening, corticosteroid enemas, corticosteroid suppositories, or
             topical treatment with 5-aminosalicyclic acid within 30 days of screening
Clinical trial NCT02589847 (phase 2, status: completed)
Conditions: clostridium difficile infection
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: standard of care antibiotics
SMILES: CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 years old.

          -  Medical record documentation of recurrent CDI including a positive C. difficile test
             within 60 days prior to enrollment and either: a) at least two recurrences after a
             primary episode and has completed at least two rounds of standard-of-care oral
             antibiotic therapy or b) has had at least two episodes of severe CDI resulting in
             hospitalization.

          -  Documented history that the subject's recurrent CDI is controlled while on antibiotics
             even if the subject is not currently on antibiotics.

          -  A positive stool test for the presence of C. difficile within 60 days prior to
             enrollment

        Exclusion Criteria:

          -  A known history of continued CDI diarrhea despite being on a course of antibiotics
             prescribed for CDI treatment.

          -  Requires continuous antibiotic therapy for a condition other than CDI.

          -  Previous successful (resolution of CDI diarrhea) fecal transplant for recurrent CDI <
             6 months prior to study enrollment.

          -  Previous unsuccessful (recurrent CDI diarrhea was unresolved) fecal transplant.

          -  Previous treatment with RBX2660.

          -  Diagnosis of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's
             disease, or microscopic colitis.

          -  Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria.

          -  History of chronic diarrhea.

          -  History of celiac disease.

          -  Disease symptoms caused by a confirmed intestinal pathogen other than C. difficile.

          -  Colostomy.

          -  Planned surgery requiring perioperative antibiotics within 3 months of study
             enrollment.

          -  Life expectancy of < 12 months.

          -  Compromised immune system
Clinical trial NCT02590588 (phase 2, status: terminated)
Conditions: amyloidosis
ICD codes: E85.89, E85.9, E85.1, E85.2, E85.3, E85.4, E85.0
Drugs: idelalisib
SMILES: [H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

        3.1.1 IgM paraprotein identified on serum immunofixation electrophoresis OR light
        chain-restricted CD20+ lymphoplasmacytic population on biopsy of bone marrow or lymph node
        (identified by H&E/immunohistochemistry or flow cytometry) OR positive myeloid
        differentiation primary response gene 88 (MYD88-L265P) OR CXCR4WHIM mutation (CXCR4
        mutation - warts, hypogammaglobulinemia, infections, myelokathexis) on submitted samples

        3.1.2 Biopsy-proven relapsed or refractory AL amyloidosis

        3.1.3 Age ≥ 18 years

        3.1.4 Eastern Cooperative Oncology Group (ECOG) performance status <2 (see Appendix A.)

        3.1.5 Difference between serum free light chains (FLC) of >30 mg/L or quantifiable IgM
        paraprotein >0.5 g/L

        3.1.6 Participants must have normal organ and marrow function as defined below:

          -  Absolute neutrophil count > 1,000/mm3

          -  Platelets > 50,000/mm3

        3.1.7 Ability to understand and the willingness to sign a written informed consent
        document.

        Exclusion Criteria:

        3.2.1 Previous treatment with idelalisib

        3.2.2 Glomerular filtration rate (GFR) <15 ml/min

        3.2.3 Cardiac biomarker Stage III disease as determined by B-type natriuretic peptide (BNP)
        >100 pg/mL and Troponin-I >0.1 ng/mL (Girnius 2014)

        3.2.4 alanine-aminotransferase (ALT)/aspartate aminotransferase (AST) values >2.5x upper
        limit of normal, Bilirubin >1.5 upper limit of normal (ULN)

        3.2.5 Central nervous system (CNS) malignancy or other active malignancy

        3.2.6 Lactating or pregnant women

        3.2.7 Exposure to another investigational drug within 4 weeks prior to start of study
        treatment

        3.2.8 Ongoing alcohol or drug addiction as determined by investigator

        3.2.9 Amyloid-directed therapy within the past 28 days

        3.2.10 History of Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV)
        (assessed by positive Hepatitis B polymerase chain reaction assay (PCR) or Hepatitis B
        Surface Antigen), and/or Hepatitis C Virus (HCV) infection

        3.2.11 t(11,14) translocation identified on bone marrow cytogenetics or by Fluorescence in
        situ hybridization (FISH)

        3.2.12 Known lytic bone lesions

        3.2.13 Positive cytomegaly virus (CMV) Polymerase chain reaction (PCR)

        3.2.14 Previously untreated AL amyloidosis (Newly diagnosed)

        3.2.15 Unwilling or unable to comply with the protocol
Clinical trial NCT02593162 (phase 2, status: completed)
Conditions: hepatitis c viral infection, chronic hepatitis c, hepatitis c (hcv), hepatitis c genotype 4
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: faldaprevir, td-6450, ribavirin
SMILES: [H][C@@](N=C(O)OC1CCCC1)(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=O)OC1=C2C=CC(OC)=C(Br)C2=NC(=C1)C1=CSC(N=C(O)C(C)C)=N1)C(C)(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic genotype 4 hepatitis C infection and HCV RNA ≥ 10^4 IU/mL at screening

          -  Hepatitis C virus treatment naive, defined as defined as having never received a
             direct acting anti-viral (DAA), and as having received ≤ 8 weeks of interferon ≥ 6
             months prior to screening

          -  Absence of cirrhosis as defined by one of the following:

               -  A liver biopsy performed within 24 calendar months of Day 1 showing absence of
                  cirrhosis

               -  Transient elastography (FibroScan®) performed within 12 calendar months of Day 1
                  with a result of ≤ 12.5 kPa

               -  A FibroSure® score ≤ 0.48 and AST:platelet ratio (APRI) ≤ 1 performed during
                  screening

        Exclusion Criteria:

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus, HIV-1 or HIV-2
Clinical trial NCT02596867 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: propanolol
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Ages 18- 65

          -  diagnosis of stage I-III breast cancer , confirmed by a core biopsy

          -  Planning to undergo definitive surgery including mastectomy or breast conserving
             surgery

          -  Systolic blood pressure must be >100 mmHg but no more than 140 mmHg and/or diastolic >
             60 mmHg and no more than 95 mmHg.

          -  normal baseline EKG

        Exclusion criteria:

          -  Pregnancy; potential subjects of female bearing age will have to complete a pregnancy
             test during screening to ensure that they are not pregnant. Potential patients who are
             post-menopausal must have confirmed one year without menstrual cycle.

          -  Free of major medical illnesses including:

          -  Uncontrolled Diabetes (HbA1c of ≤ 8 if previously tested)

          -  Uncontrolled hypertension: BP >systolic 140/ diastolic > 95

          -  Cardiac diseases (history of cardiac valve disease, coronary artery disease,
             congestive heart failure, A-V block, peripheral vascular disease, any cardiac
             arrhythmia/bradycardia) with the exception of the diagnosed cancer.

          -  Histories of asthma, bronchospastic disease, or obstructive pulmonary disease

          -  Previously diagnosed thyrotoxicosis

          -  Severe allergic reactions to medications which are included in the beta blocker family

          -  Previously or currently treated with a beta adrenergic receptor antagonist

          -  Patients with locally advanced or inflammatory breast cancer not amenable to surgical
             resection

          -  Patients taking any of the following medications will be excluded:

               -  Drugs that are categorized as digitalis glycosides, beta-blockers and calcium
                  channel blockers, ACE inhibitors and alpha blockers

               -  Amiodarone

               -  Cimetidine

               -  Ciprofloxacin

               -  Delavudin

               -  Dobutamine

               -  Ethanol

               -  Fluconazole

               -  Fluoxetine

               -  Fluvoxamine

               -  Haloperidol

               -  Imipramine

               -  Isoniazid

               -  Isoproterenol

               -  Luvoxamine

               -  Paroxetine

               -  Phenytoin

               -  Phenobarbital.

               -  Propafenone.

               -  Quinidine

               -  Reserpine

               -  Rifampin

               -  Ritonavir

               -  Rizatriptan.

               -  Tenioposide

               -  Theophylline

               -  Thyroxine

               -  Tolbutamide.

               -  Warfarin

               -  Zileuton

               -  Zolmitriptan
Clinical trial NCT02597257 (phase 2, status: unknown status)
Conditions: postherpetic neuralgia, diabetic polyneuropathy, peripheral neuropathy
ICD codes: B02.22, G90.09
Drugs: lidocaine hcl, normal saline
SMILES: CNC[C@H](O)C1=CC(O)=C(O)C=C1, O
Eligibility criteria:

        Inclusion Criteria:

          -  postherpetic neuralgia, diabetic polyneuropathy, peripheral neuropathy

          -  NRS score > 4

          -  stable oral medication during the 1 month trial period

          -  volunteers with informed consent

        Exclusion Criteria:

          -  pregnancy, breastfeeding, possibility of pregnancy

          -  pain from causes other than upper 3 indications

          -  hypersensitivity to lidocaine or other local anesthetics

          -  important disease of heart, kidney, liver or incurable disease that may affect the
             assessment of adverse effects, or may interfere with the completion of study

          -  severe conduction block

          -  history of other interventions that may affect the study

          -  Enrollment in other clinical trials within 30 days

          -  otherwise not suitable to study
Clinical trial NCT02597803 (phase 2/phase 3, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: rgn-259, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a subject reported history of dry eye for at least 6 months

          -  Have a history of use or desire to use eye drops for dry eye symptoms within 6 months

          -  Have a Schirmer's Test score of ≤10mm and ≥1mm

          -  Have a Tear Film Break-Up Time (TFBUT) ≤10 seconds

          -  Have a corneal fluorescein staining score of ≥2 in at least one region of the cornea

        Exclusion Criteria:

          -  Have any clinically significant slit-lamp findings at Visit 1 that may include active
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active
             ocular allergies that require therapeutic treatment, and/or in the opinion of the
             investigator may interfere with study parameters;

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
             ocular inflammation at Visit 1;

          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses
             during the study;

          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the
             last 6 months;

          -  Have an IOP > 25 mmHg at Visit 1;

          -  Have any planned ocular and/or lid surgeries over the study period;

          -  Be using or anticipate using temporary punctal plugs during the study that have not
             been stable within 30 days of Visit 1;

          -  Be currently taking any topical ophthalmic prescription (including medications for
             glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and
             cannot discontinue these medications for the duration of the trial (excluding
             medications allowed for the conduct of the study);

          -  Have corrected visual acuity greater than or equal to logMAR +0.7 as assessed by Early
             Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1;